查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2018796

多发性骨髓瘤治疗市场：依药物类别、给药途径、产品类型及通路划分－2026-2032年全球市场预测

Multiple Myeloma Therapeutics Market by Drug Class, Mode Of Administration, Product Type, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年多发性骨髓瘤治疗市场价值为 246 亿美元，预计到 2026 年将成长至 263.8 亿美元，复合年增长率为 7.36%，到 ​​2032 年将达到 404.8 亿美元。

主要市场统计数据
基准年 2025 246亿美元
预计年份：2026年 263.8亿美元
预测年份 2032 404.8亿美元
复合年增长率 (%) 7.36%

全面概述科学突破、不断发展的交付模式和支付方趋势如何汇聚，从而重新定义多发性骨髓瘤的治疗路径。

多发性骨髓瘤的治疗处于科学创新、不断发展的临床实践和复杂的商业性趋势交汇的关键位置。细胞疗法、标靶抗体、小分子药物和给药方法的进步正在重塑治疗路径，并重新定义疗效、耐受性和长期疾病控制的预期。这些科学进步与治疗方法的生产、报销和交付方式的结构性变革同步发生，这使得相关人员更需要整合临床、监管和营运方面的见解，并制定连贯的策略规划。

近期科学突破、监管柔软性和商业性创新如何重塑多发性骨髓瘤的治疗途径、进入模式和竞争挑战。

多发性骨髓瘤的治疗格局正在经历一场变革性的转变，这主要得益于科学突破、监管政策的调整以及商业模式的创新。细胞疗法和新一代免疫疗法正在拓展临床可行的治疗范围，使治疗模式从以细胞毒性为中心的序贯治疗方案转变为以深度缓解和延长无进展生存期为目标的持续性标靶治疗。同时，基于生物标记的患者筛选和诊断准确性的提高，使得更合理的治疗顺序和联合治疗策略成为可能，这在增加临床决策复杂性的同时，也推动了治疗的个人化进程。

了解新关税措施对下游供应链、定价和营运的影响，并掌握策略采购和製造选择如何确保准入和商业性可行性。

2025年的关税政策将为依赖跨国供应链和专业生产投入的治疗药物带来新的营运和商业复杂性。进口关税的引进和调整不仅会影响成品药，还会影响活性药物成分、生物製药原料、一次性生物加工设备和低温运输物流服务等关键组件。因此，製造商和经销商正在重新审视筹资策略、供应商合约和库存政策，以在降低成本影响的同时，维持供应的连续性。

以细分市场主导的策略挑战，旨在按药物类别、给药途径、分销管道和产品类型确定投资和商业化优先事项。

细分市场层面的洞察揭示了不同治疗领域、给药途径、通路和产品类型所面临的不同策略挑战。按药物类别划分，CAR-T疗法呈现出独特的开发和商业化模式，其特点是个人化生产、复杂的物流以及卓越中心（COE）交付模式。同时，组蛋白去乙酰化酶抑制剂作为重要的辅助性治疗，在耐受性和联合治疗方面具有潜力。免疫调节剂在核心疗法中继续发挥核心作用，其生命週期管理正透过对新製剂和联合治疗的研究来实现。单株抗体和蛋白酶体抑制剂在治疗序列中占有至关重要的地位。特别是，Bortezomib、Carfilzomib和伊沙佐米等蛋白酶体抑制剂，各自具有不同的给药方案、毒性考虑以及对临床依从性的影响，从而影响临床医生的选择。

美洲、欧洲、中东、非洲和亚太地区在实施状况、基础设施和偿还制度方面的区域差异决定了准入途径和战略投资。

区域趋势既影响多发性骨髓瘤新疗法的引入速度，也影响其应用所需的运作前提。美洲地区创新治疗方法的临床应用率持续维持高位，且拥有完善的报销体系，支持早期准入计画。然而，该地区面临严格的价格审查和以支付主导的估值框架，因此需要可靠的真实世界数据和基于疗效的合约。在欧洲、中东和非洲（EMEA）地区，监管协调、区域采购机制以及医疗基础设施的差异导致疗法应用时间有差异。虽然西欧高所得市场的疗法应用正在加速，但新兴市场则优先考虑成本效益高且扩充性的解决方案。

竞争差异化越来越依赖可扩展的生产、证据产生、与支付方的合作以及加速患者获得治疗和增强商业性永续性的伙伴关係模式。

在多发性骨髓瘤治疗领域，企业间的竞争格局日益受到核心药物发现和临床开发以外的能力的影响。组织敏捷性，例如能够大规模生产复杂的生物製药和细胞疗法，在以疗效为导向的医保报销谈判中积累经验，以及生成核准后真实世界数据（REW）的能力，如今已成为商业性成功的关键决定因素。专注于CAR-T和双特异性抗体等平台技术的企业，正在投资建构端到端的价值链，涵盖载体生产、低温物流以及治疗中心培训等各个环节，旨在缩短患者用药时间，并提高治疗效果的一致性。

为製造商和相关人员提供可操作的策略，以确保供应弹性、基于证据的价值、适应性合约和以患者为中心的交付模式，从而加速部署。

产业领导者应优先考虑一系列切实可行的倡议，使科学研究潜力与病患和商业性成果相契合。首先，他们应积极投资于生产韧性和产能多元化，以降低供应链和关税风险，包括认证替代供应商以及与契约製造製造商建立策略合作伙伴关係，以支持原料药和特种生物製药的生产。同时，应将真实世界资料（REW）的收集纳入早期研发计划，以支持监管申报、核准后的适应症扩展以及与支付方签订基于价值的合同，并确保资料收集的互通性和地域相关性。

采用严谨的混合方法研究途径，结合二手文献和针对性的相关人员访谈，来检验临床、营运和商业性影响。

支持这些发现的研究结合了结构化的二手资料回顾、有针对性的专家访谈和主题整合，建构了一个平衡且以实践为导向的观点。二手资料分析包括对同行评审的临床文献、已发布的监管文件、临床试验註册资讯和现有政策声明的审查，梳理了近期核准、扩展适应症以及临床实践的变化。这些资讯来源使我们能够揭示临床和监管背景，并专注于治疗机制、给药方法和循证医学要求，而无需依赖专有的市场规模估算或预测数据。

整合治疗创新、营运绩效和政策方面的趋势，这些趋势决定了多发性骨髓瘤患者获得治疗的速度和商业性成功。

总之，多发性骨髓瘤的治疗格局呈现出快速创新以及随之而来的复杂运作和商业需求的特征。儘管科学进步拓宽了可行的治疗策略范围，但要大规模使患者获益，需要在生产製造、物流、医保合作和临床应用等各个环节进行整合执行。价格和供应链趋势带来的新压力，使得策略采购、近岸外包以及合约柔软性成为维持药物可及性和获利能力的必要条件。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 多发性骨髓瘤治疗市场：依药物类别划分

  • CAR-T疗法
  • 组蛋白去乙酰化酶抑制剂
  • 免疫调节药物
  • 单株抗体
  • 蛋白酶体抑制剂
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米

第九章：多发性骨髓瘤治疗药物市场（依给药途径划分）

  • 静脉
  • 口服
  • 皮下

第十章 多发性骨髓瘤治疗市场：依产品类型划分

  • 品牌商品
  • 非专利的

第十一章 多发性骨髓瘤治疗药物市场：按分销管道划分

  • 医院药房
  • 零售药房
  • 专科药房

第十二章 多发性骨髓瘤治疗药物市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 多发性骨髓瘤治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 多发性骨髓瘤治疗药物市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国多发性骨髓瘤治疗市场

第十六章：中国多发性骨髓瘤治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Adaptimmune Therapeutics plc
  • Amgen Inc.
  • Arcellx, Inc.
  • AstraZeneca plc
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Genmab A/S
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd.
  • Ichnos Sciences
  • Ionis Pharmaceuticals, Inc.
  • iTeos Therapeutics
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Oncopeptides AB
  • Poseida Therapeutics, Inc.
  • Precision BioSciences, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-ED54C46E8354

The Multiple Myeloma Therapeutics Market was valued at USD 24.60 billion in 2025 and is projected to grow to USD 26.38 billion in 2026, with a CAGR of 7.36%, reaching USD 40.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.60 billion
Estimated Year [2026] USD 26.38 billion
Forecast Year [2032] USD 40.48 billion
CAGR (%) 7.36%

A comprehensive introductory perspective on how scientific breakthroughs, evolving delivery models, and payer dynamics are converging to redefine multiple myeloma care pathways

Multiple myeloma therapeutics sit at a pivotal intersection of scientific innovation, clinical practice evolution, and complex commercial dynamics. Advances in cellular therapies, targeted antibodies, small molecules, and administration modalities are reshaping treatment pathways and redefining expectations for efficacy, tolerability, and long-term disease control. These scientific advances are occurring alongside structural changes in how therapies are manufactured, reimbursed, and delivered to patients, intensifying the need for stakeholders to synthesize clinical, regulatory, and operational intelligence into coherent strategic plans.

Clinicians and health systems are navigating a wider array of therapeutic choices that span highly specialized cell therapies to more conventional proteasome inhibitors and immunomodulatory agents. Payers and policy-makers are responding to evidence on value and durability with evolving coverage frameworks and outcome-based contracting pilots. Meanwhile, manufacturers are contending with longer, more complex development pathways for advanced therapies that require parallel investments in manufacturing capacity, cold-chain logistics, and specialized workforce training. Together, these dynamics create both opportunity and risk: opportunities to deliver transformative patient benefits and capture differentiated commercial value, and risks tied to supply continuity, pricing pressures, and adoption barriers.

This introduction frames the subsequent sections, which examine the landscape shifts, tariff-related impacts on supply chains and costs, segmentation-driven insights across therapeutic classes and delivery channels, regional nuances, competitive behavior, actionable recommendations for industry leaders, and the methodology underpinning the intelligence gathered. The aim is to equip executive teams with a balanced, operationally grounded view that can inform near-term decisions and multi-year planning.

How recent scientific breakthroughs, regulatory flexibility, and commercial innovation are reshaping therapeutic pathways, access models, and competitive imperatives in multiple myeloma

The therapeutic landscape for multiple myeloma is undergoing transformative shifts driven by a confluence of scientific breakthroughs, regulatory adaptability, and commercial model innovation. Cellular therapies and next-generation immunotherapies are extending the boundaries of what is clinically feasible, prompting treatment paradigms to evolve from sequential, cytotoxic-focused regimens toward durable, targeted approaches that aim for deeper remissions and longer progression-free intervals. Parallel enhancements in biomarker-driven patient selection and diagnostic precision are enabling more rational sequencing and combination strategies, increasing the complexity of clinical decision-making while improving personalization of care.

Regulators are increasingly open to accelerated pathways and real-world evidence to inform approvals and label expansions, which shortens the time from proof-of-concept to broader clinical access but elevates the need for robust post-approval evidence generation and pharmacovigilance. Commercially, manufacturers are experimenting with innovative contracting arrangements, including outcomes-based agreements and multi-stakeholder risk-sharing constructs, to balance upfront pricing with long-term value delivery. Operationally, the rise of high-cost, capacity-constrained therapies has catalyzed collaborations between manufacturers, specialized providers, and logistics partners to manage manufacturing scale-up and equitable patient access.

Taken together, these shifts are altering competitive dynamics, with research-intensive players prioritizing cell therapy and bispecific platforms while established product classes such as proteasome inhibitors and immunomodulatory agents are being optimized through formulation changes and administration route innovations. Health systems are likewise adapting by investing in specialized centers of excellence and care pathways that can integrate new therapies while managing budgetary and infrastructure constraints. The net effect is a market environment defined by rapid innovation, increasing interdependence among stakeholders, and heightened execution risk tied to manufacturing, clinical adoption, and reimbursement alignment.

Understanding the downstream supply chain, pricing, and operational implications of new tariff measures and how strategic sourcing and manufacturing choices can preserve access and commercial viability

Tariff policies in 2025 introduced a new layer of operational and commercial complexity for therapeutics that rely on cross-border supply chains and specialized manufacturing inputs. The introduction or recalibration of import tariffs affects not only finished pharmaceutical products but also critical components such as active pharmaceutical ingredients, biologic raw materials, single-use bioprocessing equipment, and cold-chain logistics services. As a result, manufacturers and distributors are reassessing sourcing strategies, supplier contracts, and inventory policies to preserve continuity of supply while containing cost impacts.

The tariff environment has prompted a strategic pivot toward nearshoring and diversification of supplier networks, which can mitigate exposure to tariff volatility and geopolitical risk but may require capital investment and longer lead times to qualify new suppliers. In addition, increased import duties elevate the relative importance of domestic manufacturing capacity and contract development and manufacturing organization partnerships that can internalize some supply chain stages. For advanced therapies, where manufacturing yields, chain-of-identity controls, and cold-chain management are critical, tariff-induced changes to logistics and component costs can translate into higher operational complexity and potentially slower scaling of patient throughput.

From a pricing and reimbursement perspective, tariff-driven cost pressures necessitate proactive engagement with payers to demonstrate real-world value and to structure commercial arrangements that distribute risk across stakeholders. Manufacturers should consider scenario planning that quantifies potential cost impacts of tariffs on gross margins and identifies mitigations such as formulation changes that reduce dependency on tariff-exposed inputs, redesigned packaging, and logistics optimization. In summary, the 2025 tariff landscape underscores the need for strategic supply chain resilience planning, contract renegotiation, and targeted investments in local capacity to preserve access and protect commercial viability.

Segmentation-driven strategic imperatives across drug classes, administration routes, distribution channels, and product types that dictate investment and commercialization priorities

Segment-level insights reveal differentiated strategic imperatives across therapeutic classes, routes of administration, distribution pathways, and product types. Within drug classes, CAR-T therapy represents a distinct development and commercialization paradigm characterized by individualized manufacturing, complex logistics, and center-of-excellence delivery models, while Histone Deacetylase Inhibitors remain an important adjuvant class with opportunities around tolerability and combination regimens. Immunomodulatory drugs continue to play a central role in backbone therapy and are subject to lifecycle management through new formulations and combination studies. Monoclonal antibodies and proteasome inhibitors maintain an essential position in treatment sequencing; notably, proteasome inhibitors such as Bortezomib, Carfilzomib, and Ixazomib each present different administration profiles, toxicity considerations, and real-world adherence implications that influence clinician choice.

Administration mode segmentation highlights the growing preference for patient-centric delivery where feasible: intravenous delivery remains indispensable for many high-efficacy biologics and infusion-based regimens, oral therapies gain traction for convenience and chronic maintenance settings but pose adherence and drug-drug interaction management challenges, and subcutaneous formulations are increasingly developed to reduce clinic time and resource burden. Distribution channel dynamics show that hospital pharmacies continue to be critical for inpatient and infusion-delivered products, specialty pharmacies are central for managing complex therapies and coordinating patient support services, and retail pharmacies play a role in dispensing oral and maintenance medications with implications for patient adherence programs and co-pay assistance structures.

Finally, product type differentiation between branded and generic offerings drives distinct commercial strategies. Branded developers focus on innovation, evidence generation for label expansion, and premium pricing strategies underpinned by differentiated clinical data, whereas generic entrants and biosimilars emphasize cost competitiveness, formulary placement tactics, and rapid adoption in maintenance or post-patent-loss settings. Bridging these segmentation lenses enables a clearer understanding of where investment in manufacturing scale, patient support, and evidence generation will have the most meaningful impact on uptake, adherence, and long-term therapeutic positioning.

Regional adoption, infrastructure, and reimbursement contrasts that determine access pathways and strategic investments across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics shape both the pace of adoption and the operational prerequisites for delivering novel multiple myeloma therapies. The Americas continue to be characterized by high clinical adoption for innovative modalities and an advanced reimbursement ecosystem that supports early access programs; this region also faces pronounced pricing scrutiny and payer-driven value frameworks that require robust real-world evidence and outcomes-based contracting. In Europe, Middle East & Africa, regulatory harmonization, regional purchasing mechanisms, and variable healthcare infrastructure lead to heterogenous adoption timelines, with high-income markets in Western Europe accelerating uptake while emerging markets prioritize cost-effective and scalable solutions.

Asia-Pacific exhibits a complex mosaic of demand drivers: certain markets demonstrate rapid clinical uptake of novel biologics and cell therapies supported by targeted national investments in advanced therapy manufacturing capacity, while others emphasize local production and cost containment. Across regions, differences in patient demographics, comorbidity patterns, and healthcare delivery models influence ideal product profiles, such as a premium on oral convenience in ambulatory care-dominated systems or an emphasis on infusion efficiency in hospital-centric models. Supply chain resilience and local regulatory engagement strategies must be tailored to regional infrastructure realities to ensure patient access and sustainable commercialization.

Cross-region planning should therefore integrate localized evidence generation, adaptive pricing strategies, and investments in regional manufacturing or fill-finish capabilities where appropriate. Establishing partnerships with regional centers of excellence, payers, and patient advocacy organizations can accelerate acceptance and uptake, while transparent value communication and flexible contracting structures are essential to navigate differing reimbursement philosophies and budget constraints.

Competitive differentiation is increasingly anchored in scalable manufacturing, evidence generation, payer engagement, and partnership models that accelerate patient access and commercial sustainability

Competitive dynamics among companies operating in multiple myeloma therapeutics are increasingly defined by capabilities beyond core discovery and clinical development. Organizational agility in scaling complex biologic and cellular manufacturing, experience in navigating outcome-focused reimbursement negotiations, and the capacity to generate post-approval real-world evidence are now central determinants of commercial success. Companies focused on platform technologies such as CAR-T or bispecific antibodies are investing in the end-to-end value chain-ranging from vector production and cryogenic logistics to training of treatment centers-in order to reduce time-to-patient and improve consistency of outcomes.

At the same time, incumbents with established proteasome inhibitors, monoclonal antibodies, or immunomodulatory backbones are leveraging lifecycle management, combination studies, and administration route optimization to defend and extend their therapeutic roles. Strategic alliances, licensing deals, and manufacturing partnerships are common as firms seek to complement internal capabilities with external expertise in cell therapy manufacturing, digital health solutions for adherence, and specialty pharmacy networks for complex therapy coordination. Mergers and acquisitions trends reflect a blend of bolt-on acquisitions to secure manufacturing scale and larger strategic transactions aimed at building integrated platforms across discovery, development, and commercialization.

From a capabilities perspective, companies that succeed will combine deep clinical development expertise, scalable manufacturing operations, sophisticated health economics evidence generation, and nimble commercial models that can adapt to region-specific payer requirements. Leadership in patient support services, adherence management, and digital engagement tools further differentiates companies by smoothing the patient journey and demonstrating real-world value that supports payer negotiations and formulary positioning.

Actionable strategies for manufacturers and stakeholders to secure supply resilience, evidence-driven value, adaptive contracting, and patient-centric delivery models that accelerate uptake

Industry leaders should prioritize a set of pragmatic actions that align scientific potential with deliverable patient and commercial outcomes. First, invest proactively in manufacturing resilience and capacity diversification to mitigate supply chain and tariff risks, including qualification of alternate suppliers and strategic partnerships with contract manufacturers to support both bulk and specialized biologic production. Concurrently, embed real-world evidence generation into early development plans to support regulatory submissions, post-approval label expansions, and value-based contracting with payers, ensuring that data collection is interoperable and geographically relevant.

Second, design patient-centric delivery models that reduce administration burden and enhance adherence. Where clinically appropriate, pursue subcutaneous or oral formulations and integrate digital adherence tools and specialty pharmacy coordination to maintain continuity of care. Third, adopt flexible commercial contracting approaches that align pricing to measurable outcomes, exploring risk-sharing and subscription-style agreements to facilitate access while protecting long-term revenue streams. Fourth, tailor regional strategies to account for differences in infrastructure and reimbursement, prioritizing investments in local manufacturing or licensing in markets where tariffs or logistics materially affect cost-to-serve.

Finally, strengthen cross-functional capabilities by integrating regulatory, clinical, supply chain, and commercial teams early in development to anticipate adoption barriers and create executable launch plans. Leadership should also cultivate partnerships with centers of excellence and patient advocacy organizations to build trust and accelerate clinical uptake. These recommended actions collectively reduce execution risk, support sustainable access, and enable companies to convert scientific advances into durable patient and shareholder value.

A rigorous mixed-methods research approach combining secondary literature synthesis and targeted stakeholder interviews to validate clinical, operational, and commercial implications

The research underpinning these insights combined structured secondary intelligence review, targeted expert interviews, and thematic synthesis to create a balanced, practice-oriented perspective. Secondary analysis included interrogation of peer-reviewed clinical literature, public regulatory filings, clinical trial registries, and available policy statements to map recent approvals, label expansions, and changes in clinical practice. These sources informed the clinical and regulatory context without relying on proprietary market sizing or forecasting data, enabling a focus on therapeutic mechanisms, administration modalities, and evidence generation imperatives.

Primary research involved semi-structured interviews with a cross-section of stakeholders, including clinical opinion leaders, hospital pharmacy directors, specialty pharmacy operators, logistics and manufacturing experts, and payer advisors. Interviews were designed to surface operational constraints, adoption pain points, and the practical implications of tariff and supply chain shifts. Findings from primary and secondary research were triangulated to validate themes and to ensure that strategic recommendations reflect both macro-level trends and on-the-ground operational realities.

Analytical rigor was maintained through iterative synthesis and validation workshops with domain experts to challenge assumptions and refine implications. Limitations of the methodology include the evolving nature of advanced therapy manufacturing technologies and ongoing policy changes that may alter the regulatory and reimbursement landscape. Where appropriate, the research highlights areas of uncertainty and recommends ongoing evidence collection and scenario planning to adapt to emerging developments.

Synthesis of therapeutic innovation, operational execution, and policy dynamics that together determine the pace of patient access and commercial success in multiple myeloma

In conclusion, the therapeutic landscape for multiple myeloma is characterized by rapid innovation coupled with intricate operational and commercial requirements. Scientific advances are expanding the range of viable therapeutic strategies, but realization of patient benefit at scale depends on integrated execution across manufacturing, logistics, payer engagement, and clinical adoption. Tariff and supply chain dynamics have introduced new pressures that necessitate strategic sourcing, nearshoring consideration, and contractual flexibility to preserve access and margins.

Segmentation across drug class, mode of administration, distribution channels, and product type highlights where investments in evidence generation, manufacturing scale, and patient support will be most impactful. Regional heterogeneity requires tailored approaches to pricing, regulatory engagement, and infrastructure investments to match local delivery capabilities and payer expectations. Competitive success will go to organizations that marry scientific differentiation with operational excellence, robust health economics evidence, and adaptive commercial models that share risk and demonstrate long-term value.

Moving forward, stakeholders should continue to monitor regulatory developments, invest in data systems that capture real-world outcomes, and coordinate cross-functional planning early in development to optimize launch and access. By aligning innovation objectives with pragmatic execution, the therapeutic community can accelerate meaningful improvements in patient outcomes while navigating the complex commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Therapeutics Market, by Drug Class

  • 8.1. CAR-T Therapy
  • 8.2. Histone Deacetylase Inhibitor
  • 8.3. Immunomodulatory Drug
  • 8.4. Monoclonal Antibody
  • 8.5. Proteasome Inhibitor
    • 8.5.1. Bortezomib
    • 8.5.2. Carfilzomib
    • 8.5.3. Ixazomib

9. Multiple Myeloma Therapeutics Market, by Mode Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Multiple Myeloma Therapeutics Market, by Product Type

  • 10.1. Branded
  • 10.2. Generic

11. Multiple Myeloma Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Retail Pharmacy
  • 11.3. Specialty Pharmacy

12. Multiple Myeloma Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiple Myeloma Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiple Myeloma Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Multiple Myeloma Therapeutics Market

16. China Multiple Myeloma Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Adaptimmune Therapeutics plc
  • 17.7. Amgen Inc.
  • 17.8. Arcellx, Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Bluebird Bio, Inc.
  • 17.11. Bristol-Myers Squibb Company
  • 17.12. Cellectis S.A.
  • 17.13. Daiichi Sankyo Company, Limited
  • 17.14. Genmab A/S
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline plc
  • 17.17. Glenmark Pharmaceuticals Ltd.
  • 17.18. Ichnos Sciences
  • 17.19. Ionis Pharmaceuticals, Inc.
  • 17.20. iTeos Therapeutics
  • 17.21. Johnson & Johnson Services, Inc.
  • 17.22. Karyopharm Therapeutics Inc.
  • 17.23. Merck & Co., Inc.
  • 17.24. Novartis AG
  • 17.25. Oncopeptides AB
  • 17.26. Poseida Therapeutics, Inc.
  • 17.27. Precision BioSciences, Inc.
  • 17.28. Regeneron Pharmaceuticals, Inc.
  • 17.29. Roche Holding AG
  • 17.30. Sanofi S.A.
  • 17.31. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HISTONE DEACETYLASE INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 113. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 114. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 131. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 132. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 137. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 138. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PROTEASOME INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA MULTIPLE MYELOMA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)